Case report: Mantle cell lymphoma, prolymphocytoid variant, with leukostasis syndrome

Modern Pathology

Volumn 17, Issue 7, 2004, Pages 879-883

  Smith, Marc D ^a   Singleton, Timothy P ^a   Balaraman, Savitha ^a   Jaiyesimi, Ishmael ^a   O'Malley, Barbara ^a   Al Saadi, Abdul ^a   Mattson, Joan C ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Leukostasis syndrome; Mantle cell lymphoma; Prolymphocytoid variant

Indexed keywords

ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD5 ANTIGEN; CYCLIN D1; FMC7 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; PROTEIN P53; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME TRANSLOCATION 11; CYCLIN D1 GENE; EYE PAIN; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HEPATOMEGALY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOHISTOCHEMISTRY; LEUKAPHERESIS; LEUKOCYTE COUNT; LEUKOSTASIS; LEUKOSTASIS SYNDROME; LUNG INFILTRATE; LYMPHADENOPATHY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA PROLYMPHOCYTOID VARIANT; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENOMEGALY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

AGED; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CYCLIN D1; FATAL OUTCOME; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, PROLYMPHOCYTIC; LEUKOCYTE COUNT; LEUKOSTASIS; LYMPHOMA, MANTLE-CELL; MALE; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042572567     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800139     Document Type: Article

References (23)

1. Swerdlow SH, Berger F, Isaacson PI, et al. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Press: Washington, DC, 2001, pp 168-170.
2. Nelson BP, Variakojis D, Peterson LC. Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation. Mod Pathol 2002;15:1111-1120.
3. Schlette E, Bueso-Ramos C, Giles F, et al. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma [comment]. Am J Clin Pathol 2001;115:571-581.
4. Schlette E, Lai R, Onciu M, et al. Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod Pathol 2001;14:1133-1140.
5. Wong KF, So CC, Chan JK. Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia [comment]. Am J Clin Pathol 2002;117:246-251.
6. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-4494.
7. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795.
8. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000;64:190-196.
9. Cohen PL, Kurtin PJ, Donovan KA, et al Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998;101:302-310.
10. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-2078.
11. Pittaluga S, Verhoef G, Criel A, et al. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma 1996;21:115-125.
12. Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute leukemia. Ther Apher 2002;6:15-23.
13. Hunter T, Pincs J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
14. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
15. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-3695.
16. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994;84:2412-2421.
17. Ichikawa A, Hotta T, Takagi N, et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992;79:2701-2707.
18. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994-2004.
19. Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993;82:2289-2295.
20. Zoldan MC, Inghirami G, Masuda Y, et al. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996;93:475-486.
21. Pinyol M, Hernandez L, Cazorla M, et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997;89:272-280.
22. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996;87:3351-3359.
23. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol 2002;33:7-20.